Beyond the primary battle against tumors, many cancer patients face a debilitating secondary war against cachexia, a profound wasting syndrome that silently erodes the body and spirit. This severe metabolic condition, marked by unintentional weight loss and muscle deterioration, significantly
In the high-stakes world of biopharmaceutical development, the line between a groundbreaking success and a costly failure is often defined by the unforgiving logic of statistical significance, a reality Nektar Therapeutics recently confronted with its autoimmune drug, rezpegaldesleukin. The company
We're joined today by Ivan Kairatov, a leading biopharma expert whose work is at the forefront of understanding our complex relationship with the microscopic world inside us. His team's recent discoveries are reshaping how we view the common fungus Candida albicans —not just as a potential threat,
In the precise and high-stakes world of breast cancer treatment, the prevailing assumption that more detailed imaging invariably leads to better patient outcomes is facing a significant and evidence-based challenge. For years, clinicians have debated the role of preoperative magnetic resonance
A transformative shift is underway in the treatment of Acute Myeloid Leukemia, offering renewed hope for patients battling the most aggressive and resistant forms of this devastating blood cancer. For years, the prognosis for individuals with relapsed or refractory AML has been bleak, with standard
The landscape of cancer immunotherapy was shaken as Arcus Biosciences announced the termination of a pivotal Phase 3 trial for its TIGIT-targeting drug, domvanalimab. The decision, prompted by a finding of "futility," delivers a significant setback to its partner Gilead Sciences and casts further
